Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer
The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.
Source: OncLive